CIRM is paving the way for a diverse and skilled workforce in regenerative medicine throughout the Golden State. Check out this video highlighting mentors, students, clinical fellows, and program alums as they share their journey and the invaluable support they've received. #CIRM #DiversityInScience #IgnitingInnovation
California Institute for Regenerative Medicine (CIRM)
Biotechnology Research
South San Francisco, California 8,093 followers
California's Stem Cell Agency
About us
The California Institute for Regenerative Medicine (CIRM) is California's stem cell agency. Our mission is to accelerate world class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse California and world.
- Website
-
https://www.cirm.ca.gov
External link for California Institute for Regenerative Medicine (CIRM)
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- South San Francisco, California
- Type
- Government Agency
- Founded
- 2004
- Specialties
- Stem Cell Research, Regenerative Medicine, Funding Agency, and Clinical Trials
Locations
-
Primary
601 Gateway Blvd
400
South San Francisco, California 94080, US
Employees at California Institute for Regenerative Medicine (CIRM)
-
Anne-Marie Duliege
Deputy Director| C-Suite Executive | Chief Medical Officer | Board Governance | Biopharma & Nonprofit Healthcare Organizations | Drug Development…
-
Ted Goldstein
-
Maria Gonzalez Bonneville
-
Lisa Kadyk
Associate Director, Therapeutics at California Institute for Regenerative Medicine
Updates
-
Dr. Noriyuki Kasahara from the University of California, San Francisco, has received an $11.8 million award from CIRM to advance a groundbreaking clinical trial targeting newly diagnosed high-grade gliomas. This innovative gene therapy, DB107, aims to convert a harmless compound into a potent cancer-fighting drug directly within tumor cells, potentially transforming brain cancer treatment.
-
With the support of a $6 million CIRM grant, Dr. Arjun Deb and his team at UCLA are advancing a pioneering treatment for heart attack and heart failure. Their therapeutic antibody targets ENPP1 to reduce post-heart attack inflammation and fibrosis, aiming to prevent heart failure and improve patient outcomes.
CIRM awards $6 million to advance research for heart attack and heart failure treatments
http://blog.cirm.ca.gov
-
CIRM has awarded $53 million to support a range of projects, from heart failure prevention to advancing cell therapy for Parkinson’s disease and targeting various cancers. #CIRM #RegenerativeMedicine #TranslationalResearch #ClinicalResearch #ParkinsonsDisease #StemCellResearch #GeneTherapy
$53 million awarded to fund clinical and translational research
http://blog.cirm.ca.gov
-
A team of scientists at the Gladstone Institutes—with funding support from CIRM and various institutions— has created a new method to simultaneously make precise edits in multiple locations within a cell. This breakthrough uses retrons, distinct DNA sequences that code for a reverse transcriptase (RT), to modify DNA efficiently in bacteria, yeast, and human cells. The ability to edit multiple genome locations at the same time opens new possibilities for studying complex diseases and developing advanced therapies.
New One-Step Method to Make Multiple Edits to a Cell’s Genome
gladstone.org
-
The California Institute for Regenerative Medicine (CIRM) is pleased to announce the appointment of Jonathan Thomas, PhD, JD, as CIRM’s President and CEO. Dr. Thomas—who is also known as JT—previously served as the ICOC Board Chair, a position he held for 12 years up to 2023, and most recently, as CIRM’s Interim CEO. “It is a privilege to take over as the official CEO and President of this incredible organization. Over the past six months, our outstanding team has made significant strides developing a game plan for how to best use the remaining Prop 14 funds for the greatest benefits for patients throughout California. As we approach our 20th anniversary, I am eager to lead CIRM into this next phase by building on our achievements and accelerating the development of transformative therapies,” said Dr. Thomas. Read the full announcement: https://lnkd.in/dPSP7sn9
-
We are excited to announce CIRM's logo refresh! Over the past 20 years, our logo has evolved to reflect our growth and transformation. Our new design continues this tradition, embodying our commitment to innovation and excellence while staying true to our core values. This brand refresh reflects who we are today and symbolizes our dynamic future. #CIRM #LogoRefresh #BrandRefresh #NewLogo #BrandUpdate
-
Dry age-related macular degeneration (AMD) affects nearly 19.8 million people in the U.S. and leads to deteriorated central vision due to the loss of retinal pigment epithelial (RPE) cells. CIRM granted $4 million to Luxa Biotechnology LLC to support the innovative RPESC-RPE-4W therapy. This therapy aims to replace lost RPE cells and restore vision, which could be a breakthrough in treating this prevalent eye disorder. #DryAMD #NewTherapies #StemCellTherapy #StemCellResearch #RegenerativeMedicine #IndustryNews #CIRM
Advancing cell therapy research for dry age-related macular degeneration (dry AMD)
http://blog.cirm.ca.gov
-
CIRM is thrilled about the recent FDA approval of Eli Lilly and Company's Kisunla drug, an Alzheimer's treatment for adults with early symptomatic Alzheimer's disease (AD). This approval underscores the critical importance of continued research and innovation in developing treatments for Alzheimer's and other neurodegenerative diseases. Congratulations to all the researchers and scientists who have dedicated their efforts to this breakthrough. #AlzheimersResearch #AD #Alzheimers #FDAapproval #MedicalProgress #CIRM #IndustryNews
FDA approves a second Alzheimer's drug that can modestly slow disease
npr.org
-
CIRM awarded $15 million to Dr. John LeGall and Allogene Therapeutics for developing ALLO-316, an anti-CD70 CAR-T cell therapy for metastatic clear cell renal cell carcinoma. Initial Phase 1 TRAVERSE trial data shows promising anti-tumor activity. This support will advance research, expand clinical sites, and enhance patient access, offering hope for kidney cancer treatment. #Immunotherapy #CART #CellTherapy #KidneyCancer #Treatment #Cancer #CancerTreatment #NewTreatments #NewResearch #CancerResearch
Supporting a CAR-T cell trial for kidney cancer
http://blog.cirm.ca.gov